PT - JOURNAL ARTICLE AU - U Radzikowska AU - A Eljaszewicz AU - G Tan AU - N Stocker AU - A Heider AU - P Westermann AU - S Steiner AU - A Dreher AU - P Wawrzyniak AU - B Rückert AU - J Rodriguez-Coira AU - D Zhakparov AU - M Huang AU - B Jakiela AU - M Sanak AU - M Moniuszko AU - L O’Mahony AU - T Kebadze AU - DJ Jackson AU - MR Edwards AU - V Thiel AU - SL Johnston AU - CA Akdis AU - M Sokolowska TI - Rhinovirus-induced epithelial RIG-I inflammasome activation suppresses antiviral immunity and promotes inflammatory responses in virus-induced asthma exacerbations and COVID-19 AID - 10.1101/2021.11.16.21266115 DP - 2022 Jan 01 TA - medRxiv PG - 2021.11.16.21266115 4099 - http://medrxiv.org/content/early/2022/02/02/2021.11.16.21266115.short 4100 - http://medrxiv.org/content/early/2022/02/02/2021.11.16.21266115.full AB - Rhinoviruses (RV) and inhaled allergens, such as house dust mite (HDM) are the major agents responsible for asthma onset, exacerbations and progression to the severe disease, but the mechanisms of these pathogenic reciprocal virus-allergen interactions are not well understood. To address this, we analyzed mechanisms of airway epithelial sensing and response to RV infection using controlled experimental in vivo RV infection in healthy controls and patients with asthma and in vitro models of HDM exposure and RV infection in primary airway epithelial cells. We found that intranasal RV infection in patients with asthma led to the highly augmented inflammasome-mediated lower airway inflammation detected in bronchial brushes, biopsies and bronchoalveolar lavage fluid. Mechanistically, RV infection in bronchial airway epithelium led to retinoic acid-inducible gene I (RIG-I), but not via NLR family pyrin domain containing 3 (NLRP3) inflammasome activation, which was highly augmented in patients with asthma, especially upon pre-exposure to HDM. This excessive activation of RIG-I inflammasomes was responsible for the impairment of antiviral type I/III interferons (IFN), prolonged viral clearance and unresolved inflammation in asthma in vivo and in vitro. Pre-exposure to HDM amplifies RV-induced epithelial injury in patients with asthma via enhancement of pro-IL1β expression and release, additional inhibition of type I/III IFNs and activation of auxiliary proinflammatory and pro-remodeling proteins. Finally, in order to determine whether RV-induced activation of RIG-I inflammasome may play a role in the susceptibility to severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection in asthma, we analyzed the effects of HDM exposure and RV/SARS-CoV-2 coinfection. We found that prior infection with RV restricted SARS-CoV-2 replication, but co-infection augmented RIG-I inflammasome activation and epithelial inflammation in patients with asthma, especially in the presence of HDM. Timely inhibition of epithelial RIG-I inflammasome activation may lead to more efficient viral clearance and lower the burden of RV and SARS-CoV-2 infections.Competing Interest StatementCA reports research grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kuhne-Center for Allergy Research and Education, European Commissions Horisons 2020 Framework Programme Cure, Novartis Research Institutes, Astrazeneca, SciBase, Stanford University SEAN Parker Asthma and Allergy Center; advisory board of Sanofi/Regeneron, GSK and Novartis, consulting fees from Novartis; Editor-in-Chief Allergy, Co-Chair EAACI Environmental Science in Allergic Diseases and Asthma Guidelines. AE reports National Science Centre Grant No. 2020/37/N/NZ5/04144, National Centre for Research and Development No. STRATEGMED2/269807/14/NCBR/2015, National Centre for Research and Development (POLTUR3/MT-REMOD/2/2019). DJJ reports advisory board and speaker fees from AstraZeneca, GSK and Sanofi and research grants from AstraZeneca. SLJ reports grants/contracts from European Research Council ERC FP7 grant number 233015, Chair from Asthma UK CH11SJ, Medical Research Council Centre grant number G1000758, NIHR Biomedical Research Centre grant number P26095, Predicta FP7 Collaborative Project grant number 260895, NIHR Emeritus NIHR Senior Investigator; consulting fees from Lallemand Pharma, Bioforce, resTORbio, Gerson Lehrman Group, Boehringer Ingelheim, Novartis, Bayer, Myelo Therapeutics GmbH; patents issued/licensed: Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. UK patent application No. GB 0405634.7, 12March 2004. Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-Beta for Anti-Virus Therapy for Respiratory Diseases. International Patent Application No. PCT/GB05/50031, 12 March 2004. Davies DE, Wark PA, Holgate ST, JohnstonSL. Interferon Lambda therapy for the treatment of respiratory disease. UK patent application No. 6779645.9, granted15th August 2012; Participation on a data safety monitory board or advisory board: Enanta Chair of DSMB, Virtus Respiratory Research Board membership. MM reports personal payments from Astra Zeneca, GSK, Berlin-Chemie/Menarini, Lek-AM, Takeda, Celon and support for attending meetings from Astra Zeneca, GSK, Berlin-Biochemie/Menarini. UR reports board secretary position of Working Group of Genomics and Proteomics of the European Academy of Allergy and Clinical Immunology (EAACI). JRC reports Pre-doctoral grant FPI from Universidad CEU San Pablo, Swiss European Mobility Program grant from University of Zurich, EAACI Mid-term Fellowship. MiSo reports research grants from Swiss National Science Foundation, GSK, Novartis and speakers fee from AstraZeneca and board secretary position of the Basic and Clinical Immunology Section of the European Academy of Allergy and Clinical Immunology (EAACI). SS reports funding from National Center of Competence in Research (NCCR) on RNA and Disease to VT (https://nccr-rna-and-disease.ch/). VT reports grant from Swiss National Science Foundation. All other authors report no conflict of interest regarding this work.Funding StatementThis work was supported by the Swiss National Science Foundation (SNSF) grant nr 310030_189334/1, European Respiratory Society Long-term research fellowships, European Academy of Allergy and Clinical Immunology long-term research fellowship and GSK research grant (to MS), and the SNF grant nr 320030_176190 and GSK (to CA). The in vivo work was supported by the European Research Council (ERC FP7 grant number 233015); a Chair from Asthma UK (CH11SJ); the Medical Research Council Centre (grant number G1000758); National Institute of Health Research (NIHR) Biomedical Research Centre (grant number P26095); Predicta FP7 Collaborative Project (grant number 260895); and the NIHR Biomedical Research Centre at Imperial College London. SLJ is an Emeritus NIHR Senior Investigator. The in vivo transcriptome work was supported by GSK. UR, AE and MM were supported from funds from the Leading National Research Centre (KNOW) in Bialystok, Poland. JRC was supported by an FPI-CEU predoctoral fellowship and the Swiss-European Mobility Programme. HDM extract was a gift from Allergopharma AG.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The in vivo experimental infection with rhinovirus study received ethical approval from the St. Marys Hospital Research Ethics Committee (09/H0712/59). The cohort SIBRO was granted ethical permission from Switzerland and Poland (KEK/ZH/Nr. 20212/0043 Kantonale Ethik Kommission Zurich; KB/70/2013 and KB/567/2014 Bioethical Committee, Wroclaw Medical University), the cohort A got a permission from the Jagiellonian University Bioethics Committee (KBET/68/B/2008 and KBET/209/B/2011).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTranscriptome data from bronchial brushings from control individuals and patients with asthma experimentally infected with RV-A16 has been submitted to the NCBI GEO: GSE185658 and will be publicly available at the time of publication. All other data are included in the Online Supplement or are available from the corresponding author upon request. The codes for transcriptome data analysis are available here: https://github.com/uzh/ezRun (NGS), https://github.com/ge11232002/p1688-Ula (microarray). Code for Proximity Extension Assay data analysis is available from the corresponding author upon request. All codes will be publicly available at the time of publication.ASCapoptosis-associated speck-like protein containing CARDBALbronchoalveolar lavageBX795inhibitor of TBK1 and IKKεCOVID-19coronavirus disease 2019HBECshuman bronchial epithelial cellsHDMhouse dust miteIAVinfluenza A virusICAM-1intracellular adhesin molecule-1IFNinterferonIKKεinhibitor-κB kinase epsilonISGinterferon-stimulated genesMDA5melanoma differentiation-associated protein 5MOImultiplicity of infectionNLRP3NLR family pyrin domain containing 3RVrhinovirusRV-A16rhinovirus A16RIG-Iretinoic acid-inducible gene ISARS-CoV-2severe acute respiratory syndrome virus 2TBK1TANK binding kinase 1 UV-light-inactivated rhinovirus A16YVADcaspase-1 inhibitor.